Key result
Myeloperoxidase serum levels > 204.9 g/l were associated with an increased risk of subsequent cardiovascular events in patients with acute myocardial infarction (HR 6.76; 95% CI 3.37-13.56; P<0.001).
Why the study?
Does myeloperoxidase (MPO) serum level predict subsequent cardiovascular events better than hs-CRP and Troponin T in patients with acute myocardial infarction?
Cohort (n=93)
No
Does myeloperoxidase (MPO) serum level predict subsequent cardiovascular events better than hs-CRP and Troponin T in patients with acute myocardial infarction?
Effect estimate: HR 6.76 (95% CI 3.37-13.56)
p-value: p=< 0.001
Elevated myeloperoxidase serum levels are a strong independent predictor of 6-month major adverse cardiovascular events in patients with acute myocardial infarction, outperforming hs-CRP and Troponin T.
Supports MPO for post-AMI risk stratification; leaves open incremental value over hs-CRP and troponin T.
Background. Inflammation has been linked to all stages of the develop-ment of vulnerable plaque which not only causes platelet activation but also proceeded by activation of polymorphonuclear neutrophils (PMNs). Myeloperoxidase (MPO), a hemoprotein abundantly expressed by PMNs and secreted during activation, possesses potent proinflammatory prop-erties and may contribute directly to tissue injury. Among predictors of major adverse cardiovascular events (MACE) that we have been widely used and known, such as hs-CRP and Troponin T, it still unknown whether MPO also provides prognostic information in patients with acute myocar-dial infarction (AMI). Objectives. The aim of our study is to search predictive value of MPO and to compare MPO with hs-CRP and Troponin T as a predictor of MACE in patients with AMI. Methods.Cohort-prospective study was done, conducted from April to June 2006 in the emergency department of National Cardiovascular Cen-tre - Harapan Kita, (NCVC-HK), Jakarta. MPO, hs-CRP, and troponin T serum levels were assessed in 93 patients with AMI. It recorded death, re-infarctions, angina, revascularization, and heart failure during 6 months of follow-up. Results.Patients with MPO serum level > 204,9 g/l have increased risk of cardiovascular events (HR 6.76; 95% CI 3.37-13.56, P < 0.001). In statistical analysis, MPO (sensitivity 83.1%; specificity 82.4%) is a stronger independent predictor for subsequent cardiovascular events than Tropo-nin T (sensitivity 59.8%; specificity 71.6%) and hs-CRP (sensitivity 48.5%; specificity 46.1%). Conclusions.MPO serum levels powerfully predict an increased risk for subsequent cardiovascular events in patients with acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Rampengan et al. (2011) conducted a cohort in Acute myocardial infarction (n=93). Myeloperoxidase (MPO) vs. hs-CRP and Troponin T was evaluated on Subsequent cardiovascular events (death, re-infarctions, angina, revascularization, and heart failure) (HR 6.76, 95% CI 3.37-13.56, p=< 0.001). Myeloperoxidase serum levels > 204.9 g/l were associated with an increased risk of subsequent cardiovascular events in patients with acute myocardial infarction (HR 6.76; 95% CI 3.37-13.56; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: